Research ArticleBrief Communications
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
Karine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, Jan Mueller-Brand, Adrian Merlo and Dominik Cordier
Journal of Nuclear Medicine November 2015, 56 (11) 1748-1751; DOI: https://doi.org/10.2967/jnumed.115.155853
Karine Gerster-Gilliéron
1University Children’s Hospital, Zürich, Switzerland
Flavio Forrer
2Nuclear Medicine, Cantonal Hospital, St. Gallen, Switzerland
Helmut Maecke
3Nuclear Medicine, University Hospital, Freiburg, Germany
Jan Mueller-Brand
4Nuclear Medicine, University Hospital, Basel, Switzerland
Adrian Merlo
5Neurosurgery Practice, Bern, Switzerland; and
Dominik Cordier
6Neurosurgery, University Hospital, Basel, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 11
November 1, 2015
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
Karine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, Jan Mueller-Brand, Adrian Merlo, Dominik Cordier
Journal of Nuclear Medicine Nov 2015, 56 (11) 1748-1751; DOI: 10.2967/jnumed.115.155853
Jump to section
Related Articles
Cited By...
- Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
- The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma
- Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis